Eli Lilly and Co. (NYSE:LLY)‘s stock had its “buy” rating restated by equities research analysts at Leerink Swann in a report issued on Sunday. They currently have a $103.00 target price on the stock. Leerink Swann’s target price would suggest a potential upside of 25.47% from the company’s current price.
Several other equities research analysts also recently commented on the stock. SunTrust Banks Inc. reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Wednesday, June 15th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Tuesday, June 28th. Jefferies Group upped their price objective on shares of Eli Lilly and from $100.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, July 14th. BMO Capital Markets reaffirmed a “buy” rating and set a $94.00 price objective on shares of Eli Lilly and in a report on Wednesday, July 27th. Finally, Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price objective on the stock in a report on Friday, July 29th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Eli Lilly and currently has a consensus rating of “Buy” and a consensus target price of $97.06.
Shares of Eli Lilly and (NYSE:LLY) opened at 82.09 on Friday. The company’s 50 day moving average is $79.44 and its 200 day moving average is $77.49. Eli Lilly and has a one year low of $67.88 and a one year high of $88.16. The company has a market capitalization of $86.83 billion, a price-to-earnings ratio of 35.38 and a beta of 0.17.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. The company earned $5.40 billion during the quarter, compared to analyst estimates of $5.14 billion. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.90 earnings per share. Equities research analysts predict that Eli Lilly and will post $3.59 earnings per share for the current year.
In other news, insider Donald A. Zakrowski sold 1,213 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the transaction, the insider now owns 1,300 shares in the company, valued at $108,108. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $79.54, for a total transaction of $16,703,400.00. Following the completion of the transaction, the insider now owns 126,220,804 shares in the company, valued at approximately $10,039,602,750.16. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of LLY. Iowa State Bank purchased a new position in shares of Eli Lilly and during the second quarter valued at about $104,000. PineBridge Investments L.P. raised its stake in shares of Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock worth $108,000 after buying an additional 920 shares during the last quarter. Cribstone Capital Management LLC acquired a new stake in shares of Eli Lilly and during the second quarter worth approximately $117,000. Coconut Grove Bank raised its stake in shares of Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock worth $122,000 after buying an additional 50 shares during the last quarter. Finally, Physicians Financial Services Inc. raised its stake in shares of Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock worth $129,000 after buying an additional 165 shares during the last quarter. Hedge funds and other institutional investors own 74.96% of the company’s stock.
Eli Lilly and Company Profile